Baseline 18F-FDG PET/CT habitat radiomics versus dual-channel deep learning for predicting interim PET early metabolic response in diffuse large B-cell lymphoma: a comparative study - Scorecard - MDSpire

Baseline 18F-FDG PET/CT habitat radiomics versus dual-channel deep learning for predicting interim PET early metabolic response in diffuse large B-cell lymphoma: a comparative study

  • By

  • Yu He

  • Shun Wang

  • Yingchun Li

  • Xinyang Li

  • Jingkai Yi

  • Dan Wang

  • Kailin Qi

  • Yongjiang Li

  • Xiao Jiang

  • Yutang Yao

  • Ping Wu

  • Meng Zhao

  • Hao Lu

  • Taipeng Shen

  • Zhuzhong Cheng

  • Ying Kou

  • June 4, 2026

  • 0 min

Share

Clinical Scorecard: Comparative Analysis of Baseline 18F-FDG PET/CT Radiomics and Dual-Channel Deep Learning for Predicting Early Metabolic Response in Interim PET of Diffuse Large B-Cell Lymphoma

At a Glance

CategoryDetail
ConditionDiffuse Large B-Cell Lymphoma (DLBCL)
Key MechanismsBaseline 18F-FDG PET/CT habitat radiomics and dual-channel deep learning models
Target PopulationPatients with DLBCL undergoing R-CHOP or R-CHOP-like chemotherapy
Care SettingRetrospective single-center study

Key Highlights

  • Habitat radiomics model (Habitat_MLP) achieved an AUC of 0.871 with high specificity and accuracy.
  • Dual-channel deep learning model (DL_DenseNet161) achieved an AUC of 0.793.
  • Habitat radiomics model showed superior calibration and net benefit in decision curve analysis.
  • Study included 148 patients, with 101 classified as early metabolic responders (EMR).
  • Interim PET (iPET) evaluated using Deauville scores for response classification.

Guideline-Based Recommendations

Diagnosis

  • Use baseline 18F-FDG PET/CT for staging and prognostic evaluation in DLBCL.

Management

  • Consider early metabolic response (EMR) assessment using iPET for treatment adaptation.

Monitoring & Follow-up

  • Utilize Deauville 5-point scale for interim PET response evaluation.

Risks

  • Approximately 30%-40% of patients may experience inadequate response or early disease progression.

Patient & Prescribing Data

Patients with pathologically confirmed DLBCL undergoing chemotherapy.

Rituximab-based regimens (R-CHOP) are standard first-line treatments.

Clinical Best Practices

  • Implement habitat radiomics for improved prediction of treatment response.
  • Utilize dual-channel deep learning for enhanced imaging analysis.

Related Resources & Content

Original Source(s)

Related Content